REporting recommendations for tumor MARKer prognostic studies (REMARK).

REporting recommendations for tumor MARKer prognostic studies (REMARK).

Pokaži ostale verzije (4)

Despite years of research and hundreds of reports on tumor markers in oncology, the number of markers that have emerged as clinically useful is pitifully small. Often initially reported studies of a marker show great promise, but subsequent studies on the same or related markers yield inconsistent c...

Bibliografski detalji
Glavni autori:	McShane, L, Altman, D, Sauerbrei, W, Taube, SE, Gion, M, Clark, G
Format:	Journal article
Jezik:	English
Izdano:	2006

Slični predmeti

Reporting recommendations for tumor marker prognostic studies (REMARK).
od: McShane, L, i dr.
Izdano: (2005)

REporting recommendations for tumor MARKer prognostic studies (REMARK).
od: McShane, L, i dr.
Izdano: (2005)

REporting recommendations for tumor MARKer prognostic studies (REMARK)
od: McShane, L, i dr.
Izdano: (2005)

REporting recommendations for tumor MARKer prognostic studies (REMARK)
od: McShane, L, i dr.
Izdano: (2005)

Re: Reporting recommendations for tumor marker prognostic studies (REMARK) - Reply
od: McShane, L, i dr.
Izdano: (2005)

REporting recommendations for tumour MARKer prognostic studies (REMARK).
od: McShane, L, i dr.
Izdano: (2005)

Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration.
od: Altman, D, i dr.
Izdano: (2012)

Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration.
od: Altman, D, i dr.
Izdano: (2012)

Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration.
od: Altman, D, i dr.
Izdano: (2012)

Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration.
od: Altman, D, i dr.
Izdano: (2012)

Reporting recommendations for tumor marker prognostic studies.
od: McShane, L, i dr.
Izdano: (2005)

Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): An abridged explanation and elaboration
od: Sauerbrei, W, i dr.
Izdano: (2018)

Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines
od: Mallett, S, i dr.
Izdano: (2010)

Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines.
od: Mallett, S, i dr.
Izdano: (2010)

Did the reporting of prognostic studies of tumour markers improve since the introduction of REMARK guideline? A comparison of reporting in published articles
od: Sekula, P, i dr.
Izdano: (2017)

Identification of clinically useful cancer prognostic factors: what are we missing?
od: McShane, L, i dr.
Izdano: (2005)

[Diagnostic (STARD) and prognostic (REMARK) studies].
od: Altman, D, i dr.
Izdano: (2005)

Importance of the distinction between quality of methodology and quality of reporting
od: Altman, D, i dr.
Izdano: (2017)

Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond.
od: Riley, R, i dr.
Izdano: (2009)

Evidence-based assessment and application of prognostic markers: The long way from single studies to meta-analysis
od: Sauerbrei, W, i dr.
Izdano: (2006)

Primer: an evidence-based approach to prognostic markers.
od: Altman, D, i dr.
Izdano: (2005)

CLINICAL PROGNOSTIC MARKERS IN MULTIPLE-SCLEROSIS
od: Paty, D, i dr.
Izdano: (1979)

Tumor Microenvironment of Metastasis in Human Breast Carcinoma: A Potential Prognostic Marker Linked to Hematogenous Dissemination
od: Gertler, Frank, i dr.
Izdano: (2014)

hsa-mir-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer.
od: Gee, H, i dr.
Izdano: (2010)

Tumor markers
od: Hamdon Kashmola, Muhanad Ali
Izdano: (2011)

Explicit inclusion of treatment in prognostic modelling was recommended in observational and randomised settings
od: Groenwold, R, i dr.
Izdano: (2016)

Determination Of Prognostic Markers For Cervical Cancer
od: Ahmad, Rahmatul Wahida
Izdano: (2008)

Genetic prognostic markers in colorectal cancer.
od: Houlston, R, i dr.
Izdano: (1997)

Prognostic value of serum markers for prostate cancer.
od: Stenman, U, i dr.
Izdano: (2005)

Overinterpretation and misreporting of prognostic factor studies in medical oncology
od: Kempf, E, i dr.
Izdano: (2016)

Reporting bias in diagnostic and prognostic studies: time for action.
od: Rifai, N, i dr.
Izdano: (2008)

Prognostic Markers Of Resistance And Relapse In Acute Leukaemia
od: Pon, Maha Abdullah@Maha-Lakswmi
Izdano: (2003)

Genetic prognostic and predictive markers in colorectal cancer.
od: Walther, A, i dr.
Izdano: (2009)

Rational identification of prognostic markers of breast cancer
od: Ibrahim, M, i dr.
Izdano: (2014)

Reporting performance of prognostic models in cancer: a review.
od: Mallett, S, i dr.
Izdano: (2010)

Less utilized prognostic markers in acute myeloid leukaemia
od: Abdullah, Maha
Izdano: (2016)

Effectiveness and cost-effectiveness of prognostic markers in prostate cancer.
od: Calvert, N, i dr.
Izdano: (2003)

P27 is a molecular tumor marker prognostic for survival in 118 NSCLC patients (PTS) treated with radiation chemotherapy on ECOG3590
od: Martin, N, i dr.
Izdano: (2006)

A prognostic model for ovarian cancer.
od: Clark, T, i dr.
Izdano: (2001)

Prognosis and prognostic research: Developing a prognostic model
od: Royston, P, i dr.
Izdano: (2009)